176 related articles for article (PubMed ID: 21878481)
1. Is liver SUV stable over time in ¹⁸F-FDG PET imaging?
Laffon E; Adhoute X; de Clermont H; Marthan R
J Nucl Med Technol; 2011 Dec; 39(4):258-63. PubMed ID: 21878481
[TBL] [Abstract][Full Text] [Related]
2. 18F-FDG uptake and clearance in patients with compromised renal function.
Akers SR; Werner TJ; Rubello D; Alavi A; Cheng G
Nucl Med Commun; 2016 Aug; 37(8):825-32. PubMed ID: 27058366
[TBL] [Abstract][Full Text] [Related]
3. Methodologic Considerations for Quantitative 18F-FDG PET/CT Studies of Hepatic Glucose Metabolism in Healthy Subjects.
Trägårdh M; Møller N; Sørensen M
J Nucl Med; 2015 Sep; 56(9):1366-71. PubMed ID: 26159590
[TBL] [Abstract][Full Text] [Related]
4. Spatial and temporal heterogeneity of regional myocardial uptake in patients without heart disease under fasting conditions on repeated whole-body 18F-FDG PET/CT.
Inglese E; Leva L; Matheoud R; Sacchetti G; Secco C; Gandolfo P; Brambilla M; Sambuceti G
J Nucl Med; 2007 Oct; 48(10):1662-9. PubMed ID: 17873124
[TBL] [Abstract][Full Text] [Related]
5. Variability and reproducibility of hepatic FDG uptake measured as SUV as well as tissue-to-blood background ratio using positron emission tomography in healthy humans.
Kanstrup IL; Klausen TL; Bojsen-Møller J; Magnusson P; Zerahn B
Clin Physiol Funct Imaging; 2009 Apr; 29(2):108-13. PubMed ID: 19076727
[TBL] [Abstract][Full Text] [Related]
6. Comparison of tumor volumes derived from glucose metabolic rate maps and SUV maps in dynamic 18F-FDG PET.
Visser EP; Philippens ME; Kienhorst L; Kaanders JH; Corstens FH; de Geus-Oei LF; Oyen WJ
J Nucl Med; 2008 Jun; 49(6):892-8. PubMed ID: 18483085
[TBL] [Abstract][Full Text] [Related]
7. Accumulation of (18)F-FDG in the liver in hepatic steatosis.
Keramida G; Potts J; Bush J; Verma S; Dizdarevic S; Peters AM
AJR Am J Roentgenol; 2014 Sep; 203(3):643-8. PubMed ID: 25148170
[TBL] [Abstract][Full Text] [Related]
8. Dual time point 2-[18F]fluoro-2'-deoxyglucose positron emission tomography in chronic bacterial osteomyelitis.
Sahlmann CO; Siefker U; Lehmann K; Meller J
Nucl Med Commun; 2004 Aug; 25(8):819-23. PubMed ID: 15266177
[TBL] [Abstract][Full Text] [Related]
9. Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5.
Hashimoto Y; Tsujikawa T; Kondo C; Maki M; Momose M; Nagai A; Ohnuki T; Nishikawa T; Kusakabe K
J Nucl Med; 2006 Mar; 47(3):426-31. PubMed ID: 16513611
[TBL] [Abstract][Full Text] [Related]
10. Reliability of semiquantitative ¹⁸F-FDG PET parameters derived from simultaneous brain PET/MRI: a feasibility study.
Jena A; Taneja S; Goel R; Renjen P; Negi P
Eur J Radiol; 2014 Jul; 83(7):1269-1274. PubMed ID: 24813529
[TBL] [Abstract][Full Text] [Related]
11. Quantitative studies using positron emission tomography (PET) for the diagnosis and therapy planning of oncological patients.
Dimitrakopoulou-Strauss A; Strauss L
Hell J Nucl Med; 2006; 9(1):10-21. PubMed ID: 16617388
[TBL] [Abstract][Full Text] [Related]
12. Multicenter Clinical Trials Using 18F-FDG PET to Measure Early Response to Oncologic Therapy: Effects of Injection-to-Acquisition Time Variability on Required Sample Size.
Kurland BF; Muzi M; Peterson LM; Doot RK; Wangerin KA; Mankoff DA; Linden HM; Kinahan PE
J Nucl Med; 2016 Feb; 57(2):226-30. PubMed ID: 26493206
[TBL] [Abstract][Full Text] [Related]
13. Node/aorta and node/liver SUV ratios from (18)F-FDG PET/CT may improve the detection of occult mediastinal lymph node metastases in patients with non-small cell lung carcinoma.
Kuo WH; Wu YC; Wu CY; Ho KC; Chiu PH; Wang CW; Chang CJ; Yu CT; Yen TC; Lin C
Acad Radiol; 2012 Jun; 19(6):685-92. PubMed ID: 22459646
[TBL] [Abstract][Full Text] [Related]
14. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
[TBL] [Abstract][Full Text] [Related]
15. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
[TBL] [Abstract][Full Text] [Related]
16. Simplified kinetic analysis of tumor 18F-FDG uptake: a dynamic approach.
Sundaram SK; Freedman NM; Carrasquillo JA; Carson JM; Whatley M; Libutti SK; Sellers D; Bacharach SL
J Nucl Med; 2004 Aug; 45(8):1328-33. PubMed ID: 15299057
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the normal adrenal gland with 18F-FDG PET/CT.
Bagheri B; Maurer AH; Cone L; Doss M; Adler L
J Nucl Med; 2004 Aug; 45(8):1340-3. PubMed ID: 15299059
[TBL] [Abstract][Full Text] [Related]
18. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
[TBL] [Abstract][Full Text] [Related]
19. Correcting tumour SUV for enhanced bone marrow uptake: retrospective 18F-FDG PET/CT studies.
Teo BK; Badiee S; Hadi M; Lam T; Johnson L; Seo Y; Bacharach SL; Hasegawa BH; Franc BL
Nucl Med Commun; 2008 Apr; 29(4):359-66. PubMed ID: 18317301
[TBL] [Abstract][Full Text] [Related]
20. SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences.
Beaulieu S; Kinahan P; Tseng J; Dunnwald LK; Schubert EK; Pham P; Lewellen B; Mankoff DA
J Nucl Med; 2003 Jul; 44(7):1044-50. PubMed ID: 12843218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
